Adalimumab Uptake Set For A Boost As CVS Drops Humira From Formularies
US Biosimilar Rivals Favored, As AbbVie Agrees Co-Branded Humira Deal With Cordavis
US adalimumab biosimilars could soon see increased uptake after CVS Caremark announced plans to remove the Humira brand from its major national formularies entirely, in favor of biosimilars.
